SEATTLE, WA–(Marketwired – Jun 17, 2013) – Planda Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutriceutical, and pharmaceutical, today announced that the final shipment of factory equipment is expected to arrive in Durban, South Africa on the weekend of June 22nd with delivery to the Senteeko tea estate in Mpumalanga Province anticipated by the end of the month.Once the final shipment arrives, installation, calibration and optimization will commence, with an estimated completion by the end of October. This last shipment, including the massive boiler system, forms part of the Company’s proprietary extraction process.
Initial harvesting trials have been successfully completed and it was determined that a trained and labor force of 400 employees can hand pick the initial 350 hectares of tea bushes every 30 days. The rejuvenation of the tea estate and replanting of new root stock is expected to increase the hectares of farmed tea bushes to 1,000 hectares by 2018. The Company expects commercial production to commence during November 2013 with a daily volume estimated at 290 kg of total formulated Phytofare catechin complex.
During the dormant tea growing period, the processing and extraction facility can be modified with the acquisition of additional equipment to produce a Phytofare Limonoid Glycoside Complex formulated as the active ingredient for improvement of respiratory ailments including common cold, sinus, and allergies, the maintenance of capillary integrity, and management ofinflammation.
Roger Duffield, Chairman and Chief Executive Officer of Planda Biotechnology, commented, “It is an exciting period in the Company’s existence as the dreams are now reality.Through the dedication and skills of many amazing people who have contributed to this massive challenge, we can finally achieve better health and wellness through the new Phytofare botanicals.”
Planda Biotechnology, through its wholly owned subsidiaries, farms over 3,600 hectares in Barberton region, Mpumalanga province, South Africa.The Company has rejuvenated 350 hectares of tea bushes, which will increase to 550 hectares acres over the next 3 years, and is supported by the introduction of 1 million tea plantlets a year from its own established nursery to ensure increased tea leaf production to 1000 hectares in 2018.
In published research by United States Department of Agriculture – Food Chemistry 132 (2012) 1156-1160, Phytofare carotenoid extract, has shown to have improved bioavailability — the degree to which a substance becomes available to the target tissue after administration — far exceeding anything available today.Superior levels of bioavailability simply mean that the body can actually receive the benefits promised on the product label. The Company believes that its technology is the foundation for creating an entirely new family of botanical drugs that can treat a multitude of diseases and conditions safely and affordably using naturally-derived extracts.
About Planda Biotechnology, Inc.
Planda Biotechnology, Inc. and its subsidiaries develop highly bioavailable, phytonutrient rich extracts which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions.Planda Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing its patented Phytofare extracts in-house, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process.Targeted industries for the Company’s products include beverage, cosmeceutical, wellness, nutraceutical, anti-aging, and pharmaceutical.For more information, please visit http://www.plandaibiotech.com.
Safe Harbor Statement
The information provided may contain forward-looking statements and involve risks and uncertainties. Results, events and performances could vary from those contemplated. These statements involve risks and uncertainties which may cause actual results, expressed or implied, to differ from predicted outcomes. Risks and uncertainties include product demand, market competition, and Planda’s ability to meet current or future plans. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Planda is not obliged to publicly release revisions to any forward-looking statement, to reflect events or circumstances afterward, or to disclose unanticipated occurrences, except as required under applicable laws.
Continue reading here:
Plandai Biotechnology, Inc. Announces Final Shipment of Machinery to South African Production Facility
